Artelo Biosciences to Present at BIO-Europe 2026 for First Time

Artelo Biosciences has been selected to present at BIO-Europe 2026, marking the company's first-ever appearance at the prominent international life sciences conference. The presentation will center on the company's novel FABP5 inhibitor platform, which the San Diego-based biosciences firm has been advancing as a potential treatment across multiple therapeutic indications.

The showcase will feature results from the first clinical study of ART26.12, Artelo's lead FABP5 inhibitor compound. The data represent a significant milestone for the company, as it transitions from preclinical development into human clinical evidence, a stage that typically draws heightened attention from potential partners and investors at major industry forums.

Read more Survey Reveals Family Caregivers Underprepared for Post-Surgery Recovery →

FABP5, or fatty acid-binding protein 5, is a target of growing interest in drug development circles due to its involvement in a range of biological processes. Artelo's platform approach — seeking to demonstrate utility across multiple indications — could broaden the commercial and scientific appeal of the asset, though the company has not specified which additional disease areas it plans to highlight at the conference.

BIO-Europe is one of the largest partnering events in the global pharmaceutical and biotechnology sector, drawing executives, scientists, and investors from across the industry. A debut selection for a company presentation signals recognition of Artelo's pipeline progress by conference organizers. The appearance is expected to give Artelo increased visibility among potential licensing partners and collaborators at a critical juncture in its clinical development program.

Continue reading at GlobeNewswire - Industry News on Financial Services.